⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
HCM News
HUTCHMED (China) Limited American Depositary Shares
HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
globenewswire.com
HCM
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026
globenewswire.com
HCM
HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China
globenewswire.com
HCM
Intended Retirement of Independent Non-executive Director and changes of composition of board committees
globenewswire.com
HCM
HUTCHMED Reports 2025 Full Year Results and Business Updates
globenewswire.com
HCM
HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors
globenewswire.com
HCM
Hippo Cultural Media Inc. Strengthens International Expansion and Drives Innovation in Online Reading and Content Distribution Systems
globenewswire.com
HCM
HUTCHMED to Announce 2025 Final Results
globenewswire.com
HCM
HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet
globenewswire.com
HCM
AZN
HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
globenewswire.com
HCM